COMMENTARY

• Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
  October 7, 2025

• Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
  October 6, 2025

• FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
  September 30, 2025

• MHLW Grows Jittery over Supply Risks amid Rising Foreign Investments
  September 8, 2025

• Pharmacies Reel from Pricey Drug Waste, Sparking Calls for Packaging Overhaul and Price Penalties
  August 27, 2025

• As Japan’s Contract Drug Rep Ratio Rises, Expectations Grow for Specialist Talent and Flexible Workforce
  August 5, 2025

• Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
  July 28, 2025

• Taking on Solid Tumors - 9: ADCs Surge Ahead as TCEs Strive for a Foothold
  July 18, 2025

• FY2024 Sees Divergence in I/O Drug Sales, Keytruda Thrives while Rivals Face Pricing Headwinds
  July 4, 2025

• Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
  June 23, 2025

• Next Wave of ALS Drugs Emerging as Novartis, Nipro Enter Development Fray
  May 27, 2025

• Impact of US Drug Policy: President Trump Shaking the World of Pharma
  May 19, 2025

• New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
  May 8, 2025

• How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
  April 1, 2025

• Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
  March 24, 2025

• Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
  March 4, 2025

• New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
  February 10, 2025

• Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
  February 5, 2025

• Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
  January 27, 2025

• Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
  January 9, 2025

ページ